Drugs Xagena
The European Commission has approved Imbruvica ( Ibrutinib ) capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase ( BTK ) inhibitor. Ibrutinib works by blocking BTK, a protein that ...
The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...
The European Commission ( UE ) has approved Imbruvica ( Ibrutinib ) for the treatment of adult patients with Waldenström’s macroglobulinemia ( WM ) who have received at least one prior therapy, or in ...
The FDA ( Food and Drug Administration ) has approved Imbruvica ( Ibrutinib ) as a first-line treatment for patients with chronic lymphocytic leukemia ( CLL ). The approval is based on data from the ...
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion, recommending broadening the existing marketing authorisation for Im ...
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion recommending approval of a new treatment option with Ibrutinib ( Imbr ...
